New Frontiers in the Treatment of Acute Myeloid Leukemia (AML): Patient-Centric Navigation in the Age of Personalized Care

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2019 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 1, 2020 to January 1, 2021

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Astellas and Jazz Pharmaceuticals

Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults and its incidence increases with age. AML has several subtypes for which treatment and prognosis vary and despite 40 years of research, the five-year survival rate has not improved in older patients. Fortunately, new options are able to target specific mutations, to include FLT3, and have been approved for the first time since 1990. Thankfully the AML treatment paradigm has begun to dramatically change, as novel targeted agents have shown improved efficacy and safety outcomes, especially in relapsed or refractory disease. For this reason, it is critical that these HCPs are educated and updated on these emerging options and strategies for their implementation into the treatment paradigm, which will ultimately improve patient outcomes in the AML patient population.

Upon completion of this activity, participants will be able to:

  • Describe the factors that contribute to poor clinical outcomes and the economic burden of AML

  • Analyze the efficacy, safety and mechanisms of action of novel therapeutics in AML, including newer targeted, cytotoxic, and antibody-based strategies, in a range of patient populations

  • Examine the role of newer cytotoxic therapy options in the evolving treatment paradigm in AML

  • Review the impact of intensive treatment initiation for AML in older populations

  • Discuss strategies to manage treatment-related adverse events in patients with AML on therapy with regimens containing novel components

  • Transform therapeutic advances and resource utilization data into informed plan decisions and formulary discussions

Faculty: Richard Stone, MD
Professor of Medicine
Harvard Medical School
Chief of Staff
Director, Adult Acute Leukemia Program
Dana-Farber Cancer Institute


Dr. Stone serves on an advisory board for Amgen, Astellas, and Trovagene. He serves as a consultant for AbbVie, Arog, Biolinerx, Celgene, Daiichi-Sankyo, Novartis, and Pfizer. He has received research/grant support from AbbVie, Arog, Argenx, Celgene, Novartis, and Takeda. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by educational grants from
Astellas and Jazz Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue